E. Webb

发表

SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.

John C. Lee, J. Adams, J. Adams, 2000, American journal of physiology. Lung cellular and molecular physiology.

SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.

S. Christensen, A. Badger, S. Christensen, 1998, The Journal of pharmacology and experimental therapeutics.

Induction of plasma exudation and inflammatory cell infiltration by leukotriene C4 and leukotriene B4 in mouse peritonitis

D. Griswold, E. Webb, L. Hillegass, 1991, Inflammation.

Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responses.

J. Lee, D. Maley, D. Cassatt, 1994, International journal of immunopharmacology.

Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.

J. Boehm, S. Kassis, J. Adams, 1998, Bioorganic & medicinal chemistry letters.

Tyrosine urea muscarinic acetylcholine receptor antagonists: achiral quaternary ammonium groups.

H. Sarau, J. Foley, Yonghui Wang, 2012, Bioorganic & medicinal chemistry letters.

Design, synthesis and structure-activity relationship of N-substituted tropane muscarinic acetylcholine receptor antagonists.

Zehong Wan, H. Sarau, J. Foley, 2012, Bioorganic & medicinal chemistry letters.

Discovery of novel 8-azoniabicyclo[3.2.1]octane carbamates as muscarinic acetylcholine receptor antagonists.

J. Foley, K. Belmonte, Haibo Xie, 2007, Bioorganic & medicinal chemistry letters.

Phlogistic activity of leukotriene D4 in the mouse

M. A. Clark, S. Mong, D. Griswold, 1986, Inflammation.

SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.

H. Sarau, G. Poste, J. Gleason, 1987, Biochemical pharmacology.

Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.

H. Sarau, J. Foley, F. Barone, 2000, The Journal of pharmacology and experimental therapeutics.

In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity.

H. Sarau, J. Foley, S. Van Horn, 1999, Prostaglandins, leukotrienes, and essential fatty acids.

Inhibition of carrageenan-induced inflammation by urethan anesthesia in adrenalectomized and sham-operated rats.

D. Griswold, D. T. Walz, E. Webb, 1982, Journal of pharmacological methods.

Inhibition of inflammatory cell infiltration by bicyclic imidazoles, SK&F 86002 and SK&F 104493

P. Bender, S. Hoffstein, N. Hanna, 1989, Inflammation.

Arachidonic acid-induced inflammation: Inhibition by dual inhibitor of arachidonic acid metabolism, SK&F 86002

N. Hanna, D. Griswold, E. Webb, 1987, Inflammation.

Pharmacology of the pyrroloimidazole, SK&F 105809--I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.

H. Sarau, J. Lee, P. Bender, 1991, Biochemical pharmacology.

Pharmacology of the pyrroloimidazole, SK&F 105809--II. Antiinflammatory activity and inhibition of mediator production in vivo.

J. Lee, N. Hanna, D. Griswold, 1991, Biochemical pharmacology.

Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists.

J. Foley, F. Blaney, M. Salmon, 2009, Journal of medicinal chemistry.

Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response

J. R. White, T. Torphy, D. Griswold, 1993, Inflammation.

Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4‐specific monoclonal antibodies: CD4+ T‐cell depletion is not required

P. Podolin, A. Truneh, D. Griswold, 2000, Immunology.

Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity.

J. Boehm, S. Kassis, J. Adams, 2001, Bioorganic & medicinal chemistry letters.

Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.

J. Adams, R. Garigipati, L. A. Yodis, 1996, Journal of medicinal chemistry.

Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.

D E Griswold, J. Boehm, S. Kassis, 1998, Bioorganic & medicinal chemistry letters.

Antiinflammatory activity of topical auranofin in arachidonic acid‐ and phorbol ester‐induced inflammation in mice

D. Griswold, E. Webb, L. Hillegass, 1995 .

Beneficial effects of SK&F 105685 in rat adjuvant arthritis: prophylactic and therapeutic effects on disease parameter progression.

A. Badger, P. Bugelski, B. Swift, 1993, International journal of immunopharmacology.

Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.

H. Sarau, J. Foley, N. Elshourbagy, 1997, The Journal of pharmacology and experimental therapeutics.

Pharmacological Characterization of GSK573719 (Umeclidinium): A Novel, Long-Acting, Inhaled Antagonist of the Muscarinic Cholinergic Receptors for Treatment of Pulmonary Diseases

H. Sarau, J. Foley, W. Rumsey, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Discovery of novel and long acting muscarinic acetylcholine receptor antagonists.

Dwight M. Morrow, Wei-Chang Fu, H. Sarau, 2008, Journal of medicinal chemistry.

Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.

J. Boehm, John C. Lee, J. Adams, 2000, Arthritis and rheumatism.

Intralesional cytokines in chronic oxazolone-induced contact sensitivity suggest roles for tumor necrosis factor alpha and interleukin-4.

D. Griswold, E. Webb, S. J. Newsholme, 1998, The Journal of investigative dermatology.

SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.

R R Osborn, D E Griswold, J. Adams, 2000, The Journal of pharmacology and experimental therapeutics.

Microprocessor-assisted plethysmograph for the measurement of mouse paw volume.

D. Griswold, E. Webb, 1984, Journal of pharmacological methods.

Effects of scalaradial, a type II phospholipase A2 inhibitor, on human neutrophil arachidonic acid mobilization and lipid mediator formation.

L. Marshall, A. Roshak, C. Sung, 1994, The Journal of pharmacology and experimental therapeutics.

Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD.

Zehong Wan, H. Sarau, J. Foley, 2009, Bioorganic & medicinal chemistry letters.

Design, synthesis, and structure-activity relationship of tropane muscarinic acetylcholine receptor antagonists.

Zehong Wan, Wei-Chang Fu, H. Sarau, 2009, Journal of medicinal chemistry.

Discovery of biphenyl piperazines as novel and long acting muscarinic acetylcholine receptor antagonists.

Zehong Wan, Dwight M. Morrow, H. Sarau, 2008, Journal of Medicinal Chemistry.

Renal effects of cyclooxygenase inhibitors in volume-depleted dogs

J. Adams, R. Palmer, D. Brooks, 2004, InflammoPharmacology.

Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism.

D. Griswold, P. Marshall, E. Webb, 1991, Agents and actions. Supplements.